Key facts
- This page summarizes Michael P. Manzo's Form 4 filing for EYEGATE PHARMACEUTICALS INC (KPRX).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 04 Aug 2021, 17:46.
Michael P. Manzo - 03 Aug 2021 Form 4 Insider Report for EYEGATE PHARMACEUTICALS INC (KPRX)
- Reporting relationship
- VP of Engineering
- Issuer ticker
- KPRX
- Reported as of
- 03 Aug 2021
- Net transaction value
- -$156
- SEC form
- 4
- Accepted by SEC
- 04 Aug 2021, 17:46:17 UTC
- Prior SEC filing
- 06 Jul 2021
- Source filing
- View source filing
- Reporting owner signature
- /s/ Sarah Romano, Attorney-in-Fact*
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Michael P. Manzo filed Form 4 for EYEGATE PHARMACEUTICALS INC (KPRX) on 04 Aug 2021.
Change
- Previous filing in this sequence was filed on 06 Jul 2021.
- Current net transaction value: -$156.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
KPRX
transaction
Common Stock
Tax liability
- Transaction value
- $156
- Shares
- -65
- Change %
- -0.42%
- Price
- $2.40
- Shares after
- 15,378
- Date
- 03 Aug 2021
- Ownership
- Direct
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
Sale of shares to cover taxes due on restricted stock that vested on 08/01/2021.